Exelixis Quarterly Cash Flow Statement
NASDAQ: EXELHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Exelixis free cash flow
In the quarter ended Jul 3, 2026, Exelixis generated $307.7 million of operating cash flow and spent $6.8 million on capital expenditures. That left free cash flow of $300.9 million, a free-cash-flow margin of 47.9% of revenue. Free cash flow was up 552.0% from the prior year's $46.2 million.
Exelixis returned $323.0 million to shareholders through share repurchases, equal to 107% of free cash flow.
Summary generated from market data by MetaCap's automated system. Methodology
Exelixis cash flow statement (quarterly)
| Quarter (USD) | Q2 20262026-07-03 | Q1 20262026-04-03 | Q4 20252026-01-02 | Q3 20252025-10-03 | Q2 20252025-07-04 | Q1 20252025-04-04 | Q4 20242025-01-03 | Q3 20242024-09-27 | Q2 20242024-06-28 | Q1 20242024-03-29 | Q4 20232023-12-29 | Q3 20232023-09-29 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | 212.05M | 210.47M | 244.53M | 193.58M | 184.85M | 159.62M | 139.86M | 117.97M | 226.12M | 37.32M | 85.52M | 1.04M |
| Net Income growth (YoY) | +14.72% | +31.86% | +74.84% | +64.09% | -18.25% | +327.73% | +63.55% | +11232.66% | +178.54% | -6.77% | — | -98.58% |
| Depreciation & Amortization | 6.98M | 6.95M | 6.95M | 7.42M | 7.34M | 7.34M | 7.64M | 7.45M | 7.33M | 6.38M | 6.53M | 6.30M |
| Stock-Based Compensation | 32.56M | 29.05M | 20.10M | 30.89M | 36.07M | 25.93M | 26.35M | 23.02M | 25.35M | 19.11M | 24.31M | 40.48M |
| Change in Working Capital | 42.92M | -620.00K | -72.96M | 44.79M | -180.26M | 17.24M | 104.25M | 57.65M | -145.90M | -29.46M | 24.35M | -24.75M |
| Operating Cash Flow | 307.74M | 251.84M | 333.51M | 290.32M | 48.99M | 211.44M | 240.26M | 271.34M | 119.55M | 68.82M | 10.57M | 117.37M |
| Capital Expenditures | -6.82M | -1.51M | -1.16M | -1.48M | -2.84M | -2.95M | -3.98M | -8.20M | -6.57M | -9.69M | -13.13M | -9.37M |
| Investing Cash Flow | 91.43M | -51.07M | 27.24M | 25.41M | 248.03M | 49.76M | -93.20M | -217.15M | 81.77M | 111.79M | 61.74M | 34.69M |
| Share Repurchases | -322.97M | -430.35M | -257.62M | -104.03M | -301.92M | -283.93M | -190.41M | -11.93M | -264.32M | -185.38M | -209.30M | -216.84M |
| Financing Cash Flow | -343.88M | -457.11M | -254.57M | -103.86M | -316.34M | -294.82M | -188.03M | 5.70M | -262.42M | -184.05M | -206.17M | -219.67M |
| Net Change in Cash | 55.30M | -256.34M | 106.19M | 211.87M | -19.32M | -33.62M | -40.97M | 59.89M | -61.10M | -3.43M | -133.87M | -67.62M |
| Free Cash Flow | 300.93M | 250.34M | 332.36M | 288.84M | 46.16M | 208.49M | 236.29M | 263.14M | 112.98M | 59.13M | -2.56M | 107.99M |
This table shows 12 quarterly periods of Exelixis's cash flow statement, from Q2 2026 back to Q3 2023, across 13 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow EXEL's reporting calendar. What is a cash flow statement?